Edition:
United Kingdom

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

232.00DKK
19 Jan 2018
Change (% chg)

kr.6.50 (+2.88%)
Prev Close
kr.225.50
Open
kr.225.50
Day's High
kr.234.20
Day's Low
kr.225.00
Volume
422,366
Avg. Vol
316,470
52-wk High
kr.444.00
52-wk Low
kr.183.00

Chart for

About

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate... (more)

Overall

Beta: 1.27
Market Cap(Mil.): kr.9,290.57
Shares Outstanding(Mil.): 31.98
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Bavarian Nordic Initiates Clinical Trial With Novel Cancer Immunotherapy

* REG-BAVARIAN NORDIC ANNOUNCES INITIATION OF CLINICAL TRIAL WITH NOVEL CANCER IMMUNOTHERAPY TARGETING BRACHYURY IN CANCER METASTASIS

19 Jan 2018

Merkel's allies, further defying SPD, seek cuts to tax and asylum seeker benefits

BERLIN Germany's Bavarian conservatives are pressing for corporate tax cuts and cuts to welfare payments for asylum seekers, which could complicate talks with the Social Democrats (SPD) on forming a new government.

01 Jan 2018

BRIEF-Bavarian Nordic Q3 EBIT at DKK 432 million

* Q3 EBIT DKK 432.0 ‍​ MILLION VERSUS LOSS DKK 124.8 MILLION YEAR AGO

08 Nov 2017

SGS and Bavarian Nordic developing challenge strain to combat respiratory virus​

ZURICH SGS and Bavarian Nordic are teaming up to develop a virus challenge strain to combat a common respiratory illness.

12 Oct 2017

SGS and Bavarian Nordic developing challenge strain to combat respiratory virus​

ZURICH, Oct 12 SGS and Bavarian Nordic are teaming up to develop a virus challenge strain to combat a common respiratory illness.

12 Oct 2017

Bavarian Nordic eyes more U.S. government contracts after new vaccine order

COPENHAGEN Danish drug maker Bavarian Nordic expects to win further U.S. contracts for its smallpox vaccine after it secured a key government order, the company said on Thursday.

28 Sep 2017

BRIEF-Bavarian Nordic wins big smallpox vaccine order for U.S. government

* SECURES CONTRACT AWARD FOR SUPPLY OF FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE TO THE U.S. GOVERNMENT

28 Sep 2017

BRIEF-Bavarian Nordic provides update on its RSV vaccine

* REG-BAVARIAN NORDIC PROVIDES UPDATE ON ITS UNIVERSAL RSV VACCINE

21 Sep 2017

BRIEF-Bavarian Nordic says independent Data Monitoring Committee determined continuation of Phase 3 prospect study of Prostvac is futile

* Independent Data Monitoring Committee recommends discontinuation of Bavarian Nordic's Phase 3 study of Prostvac in metastatic prostate cancer

14 Sep 2017

Bavarian Nordic says first milestone payment under J&J deal could be in 2019

COPENHAGEN Danish biotech company Bavarian Nordic expects to get its first milestone payment under a deal with Janssen Pharmaceuticals in 2019, if clinical trials for vaccines targeting hepatitis B and HIV-1 get underway next year, a company executive said.

25 Aug 2017

Earnings vs. Estimates